A global life sciences and healthcare company is closing a Massachusetts facility and laying off nearly 100 people.
For the full fiscal year 2025, Wall Street analysts expect Labcorp’s diluted EPS to grow by 12% annually to $16.32, followed ...
The move adds Labcorp’s US biocompatibility, analytical testing, and preclinical research services to Namsa’s operations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback